Risk factors to remember in COVID-19-related thrombosis4,37
| COVID-19 infection . | COVID-19 (adenovirus) vector vaccines . |
|---|---|
| Older age (>75) | Middle age (18-49) |
| Male | Female |
| Obesity | Platelet count <150 |
| Hypertension | Splanchnic vein and cerebral vein thrombosis reported in higher rates |
| Prior cardiac disease | |
| Active cancer or recent anticancer treatment | |
| Elevated D-dimer, FDP, LA | |
| VTE in lower-extremity deep veins and PE commonly seen |
| COVID-19 infection . | COVID-19 (adenovirus) vector vaccines . |
|---|---|
| Older age (>75) | Middle age (18-49) |
| Male | Female |
| Obesity | Platelet count <150 |
| Hypertension | Splanchnic vein and cerebral vein thrombosis reported in higher rates |
| Prior cardiac disease | |
| Active cancer or recent anticancer treatment | |
| Elevated D-dimer, FDP, LA | |
| VTE in lower-extremity deep veins and PE commonly seen |
FDP, fibrin degradation products.